Form 6-K GENETIC TECHNOLOGIES For: Jul 05

 

 

FORM 6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

 

dated July 5, 2022

 

Commission File Number 0-51504

 

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

 

N/A

(Translation of Registrant’s Name)

 

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes ☐ No ☒

 

If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: July 5, 2022

 

	GENETIC TECHNOLOGIES LIMITED
	By:	/s/ Mike Tonroe
	Name:	Mike Tonroe
	Title:	Company Secretary

 

 

EXHIBIT INDEX

 

Exhibit		Description of Exhibit
99.46		20220705 – Mike Tonroe – Copany Secretary Resignation FINAL

 

 

Exhibit 99.46

 

ASX Market Announcement

 

Mike Tonroe - Company Secretary Resignation

 

Melbourne, Australia, 4 July 2022: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease advises that Mr Michael Tonroe has resigned as Chief Financial Officer (CFO) and Company Secretary of the Company to pursue other opportunities.

 

The Company will commence a search process for a new CFO and Company Secretary with requisite dual ASX and Nasdaq listed company expertise, with a specific focus on managing global sales and will provide a further market update in due course.

 

Mr Tonroe leaves GTG at a time of expansion in its geneType brand internationally and emerging presence in the US and European market and with US payers. The Company’s direct-to-consumer EasyDNA brand continues to capitalize on growth opportunities in the US, Europe and Asia.

 

Simon Morriss, CEO of GTG commented on behalf of the GTG team “Mike joined GTG in 2021 and has become a valued member of the Executive team. Mike has played a key role in driving our commercialisation and acquisition strategies. We extend our appreciation to Mike for his outstanding contributions to the Company during his tenure and wish him well in his future endeavours.”

 

Mr Tonroe will remain Company Secretary and CFO until the completion of the transition of duties to an interim or permanent replacement with global sales experience will be actively recruited.

 

-END-

 

Authorised for release by the board of directors of Genetic Technologies Limited

 

Enquiries

 

Investor Relations

Justin Foord

Market Eye

M: +61 402 600 691

E: [email protected]

 

About Genetic Technologies Limited

 

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals. Leading the world in risk prediction in Oncology, Cardiovascular and Metabolic diseases. Genetic Technologies continues to develop a pipeline of risk assessment products. For more information, please visit www.genetype.com

 

Genetic Technologies Limited www.genetype.com [email protected] ABN 17 009 212 328

60-66 Hanover Street Fitzroy Victoria 3065 Australia +61 3 8412 7000

 

 

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Genetic Technologies Announces Closing of US$2 Million Registered Direct Offering
• TEAMSTERS-BACKED WORKER FREE SPEECH BILL PASSES RHODE ISLAND SENATE LABOR COMMITTEE
• Sungrow Released Annual Report 2023: Operating Revenue Witnessed A Robust Growth of 79.5%